Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
T-ReX study: Tocilizumab with reducing and stopping methotrexate in rheumatoid arthritis
jRCTs041180071Completed
- Sponsor
- Chugai Pharmaceutical Co., Ltd.
- Start
- Oct 2016
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Open-label, single-arm trial of tocilizumab in rheumatoid arthritis (RA), sponsored by Chugai Pharmaceutical Co., Ltd. Primary endpoint: Maintenance of low disease activity at week 36. Started Oct 2016; status: completed.
02
Drugs
tocilizumab
03
Conditions
rheumatoid arthritis (RA)
Beyond the preview
Go deeper on jRCTs041180071.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCTs041180071.